Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 Biomarker group CTD_human Loss of metallothionein predisposes mice to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-kappaB target genes. 21159647 2011
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 AlteredExpression group BEFREE Protein expression in hepatoma HepG2 cells stimulated by TGF-beta(1) was analyzed by western blotting and plasminogen activator inhibitor type 1 (PAI-1) transcriptional activity in HepG2 cells was evaluated. 19793165 2010
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 Biomarker group BEFREE Ghrelin, a recently described orexigenic peptide hormone, attenuates PAI-1 induced by TNF-alpha in the human hepatoma cell line (HepG2). 18700166 2008
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 AlteredExpression group BEFREE The MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2. 17384280 2007
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 AlteredExpression group BEFREE Cotransfection of human or rat PAI-1 promoter luciferase constructs with expression vectors for wild-type USF-2 or USF-2 mutants in human HepG2 and rat H4IIE cells as well as in primary rat hepatocytes revealed that the effects of USF on PAI-1 expression depend on the cell type rather than the promoter context and that the USF-specific region domain of USF accounts for the observed cell type-specific effects. 16330554 2006
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 AlteredExpression group BEFREE IGF-1 was shown to enhance PAI-1 expression in primary hepatocytes and HepG2 hepatoma cells, but the molecular mechanisms underlying this effect have not been fully elucidated. 15968405 2005
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 Biomarker group BEFREE In this study we characterize the hypoxia-mediated induction of PAI-1 in human hepatoma cell line HepG2. 11877282 2002
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 AlteredExpression group BEFREE We have characterized the regulation of plasminogen activator inhibitor-1 (PAI-1) gene expression by phorbol 12-myristate 13-acetate (PMA), serum, and interleukin-1alpha (IL-1alpha) in the human hepatoma cell line HepG2. 9888864 1999
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 AlteredExpression group BEFREE These data suggest that overexpression of Pgp in these hepatoma cells may covariate with the phenotypes of both enhanced in vitro invasiveness and high PAI-1 expression, whether randomly acquired or not. 9802060 1999
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 Biomarker group BEFREE Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. 8034668 1994
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 Biomarker group BEFREE Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. 8387542 1993
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 Biomarker group BEFREE Thus, these data clearly show that LRP is the major cell-surface receptor responsible for t-PA.PAI-1 complex binding and endocytosis on human hepatoma HepG2 cells and extend the multifunctional nature of LRP as an endocytosis receptor for several structurally and functionally distinct ligands. 8389767 1993
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.400 AlteredExpression group BEFREE In the current work we have analyzed the regulation of vitronectin by transforming growth factor-beta 1 (TGF beta 1) in this hepatoma cell line by Northern hybridization, polypeptide and immunoprecipitation analyses and compared the response to another TGF beta-regulated gene, plasminogen activator inhibitor (PAI-1). 1712727 1991